Treatment of Tracheal Cancer in Advanced Adenoid Cystic Carcinoma with Significant Disease Progression
Adenoid cystic carcinoma (ACC) is one of the two most common primary tracheal malignancies in adults and presents distinct management challenges when it reaches an advanced stage with marked disease progression and clinical symptoms.
Clinical Scenario
This protocol applies to patients with adenoid cystic carcinoma of the trachea who have significant disease progression and are experiencing symptoms of advanced disease. ACC, along with squamous-cell carcinoma, accounts for more than two-thirds of primary tracheal tumors in adults.
Treatment Approach
For this population, the treatment approach involves molecular profiling-guided therapy. Next-generation sequencing (NGS) plays a role in informing later-line treatment decisions when standard options have been exhausted — full details of agent selection and sequencing are in the structured protocol.
The complete regimen, decision algorithm, and evidence-graded recommendations are available via the link below.
References
- The most common types are squamous-cell carcinoma (SCC) and adenoid cystic carcinoma (ACC), which together account for more than two-thirds of primary tracheal tumors in adults.
- Consider multi-agent chemotherapy for patients with advanced ACC exhibiting significant disease progression and symptoms [II, B].
- In patients with symptoms of advanced disease, multi-agent chemotherapy may be considered.
- Consider targeted therapies based on molecular profiling for patients with advanced tracheal tumors [III, B].
- Thus, NGS may be recommended for later lines of therapy, when standard treatment options are exhausted, and there is a need to explore targeted therapies based on the specific genetic profile of the tumor.
DOI: 10.3389/or.2024.1451247
View source ↗